Apellis Pharmaceuticals Inc
222 articles about Apellis Pharmaceuticals Inc
-
Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
4/21/2022
Apellis Pharmaceuticals, Inc. today announced results from a global survey conducted by The Harris Poll, which found that living with geographic atrophy (GA) can cause a substantial emotional burden and impact on independence.
-
Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
4/4/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 3:00 p.m. ET.
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Mar 24, 2022
3/24/2022
Apellis Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 7,446,809 shares of its common stock at a public offering price of $47.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.
-
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock - Mar 23, 2022
3/23/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that it has commenced an underwritten public offering of $300 million of its common stock.
-
It was a busy week for clinical trial announcements. Here's a look.
-
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
3/16/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for the treatment of GA secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Mar 02, 2022
3/2/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will participate in the following investor conferences in March.
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
2/28/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2021 financial results and business highlights.
-
Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results
2/22/2022
Apellis Pharmaceuticals today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results on Monday, February 28, 2022 at 4:30 p.m. ET.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2022
1/6/2022
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to one new employee with a grant date of January 3, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company.
-
Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Apellis Pharmaceuticals today announced that the company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
12/15/2021
The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving haemoglobin levels 1.
-
Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
12/15/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB announced today that the European Commission (EC) has approved Aspaveli® (pegcetacoplan), the first and only targeted C3 therapy, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who are anemic after treatment with a C5 inhibitor for at least three months.
-
Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population
12/13/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today new data demonstrating that Empaveli™/Aspaveli® (pegcetacoplan) provides consistent, sustained normalization of clinical measures across patients with paroxysmal nocturnal hemoglobinuria (PNH) who are treatment-naïve and patients with baseline hemoglobin levels greater than or equal to 10.0 g/dL.
-
Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
11/29/2021
Apellis Pharmaceuticals, Inc. today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET.
-
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares - Nov 18, 2021
11/18/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares at the public offering price of $40.00 per share.
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Nov 16, 2021
11/16/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced the pricing of its underwritten public offering of 8,750,000 shares of its common stock at a public offering price of $40.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock - Nov 15, 2021
11/15/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that it has commenced an underwritten public offering of $300 million of its common stock.